Electronic Supplementary Material (ESI) for Organic Chemistry Frontiers. This journal is © the Partner Organisations 2015

Supporting Information

Selective Syntheses of Leuconolam, Leuconoxine, and

Mersicarpine Alkaloids from a Common Intermediate through

Regiocontrolled Cyclizations by Staudinger Reactions

Zining Li, Qian Geng, Zhe Lv, Beau P. Pritchett, Katsuaki Baba, Yoshitaka Numajiri, Brian M. Stoltz* and Guangxin Liang*

State Key Laboratory and Institute of Elemento-organic Chemistry, Collaborative Innovation Center of Chemical Science and Engineering (Tianjin), Nankai University, Tianjin, China, 300071

lianggx@nankai.edu.cn

The Warren and Katharine Schlinger Laboratory of Chemistry and Chemical Engineering, Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena,

California 91125

stoltz@caltech.edu

Table of Contents

General information	S-1
Experimental procedures	S-1–S-12
Table of NMR spectroscopic data comparison	S-13–S-17
Reference and Note	S-18
NMR Spectra	S-19–S-52
HRMS Spectra of Compound 21	S-53

General information:

All air and moisture sensitive reactions were performed under an atmosphere of argon. Reagents obtained from Acros, Aldrich, J&K, and Aladdin were used without further purification. THF and toluene were dried by distillation over Na/benzophenone. MeCN, CH₂Cl₂, CCl₄ and NEt₃ were dried by distillation over CaH₂, DMF was dried by distillation over CaH₂ under reduced pressure. MeOH was dried by distillation over Mg turnings. TLC inspections were on silica gel GF254 plates. Column chromatography was performed on silica gel (200–300 mesh).

¹H NMR and ¹³C NMR spectra were recorded on a Bruker AVANCE AV400 (400MHz and 100MHz). Signal positions were recorded in ppm with the abbreviations s, d, t, m, and bs denoting singlet, doublet, triplet, multiplet, and broad singlet respectively. All NMR chemical shifts were referenced to residual solvent peaks or to Si(CH₃)₄ as an internal standard, spectra recorded in CDCl₃ were referenced to residual CHCl₃ at 7.26 ppm for ¹H NMR or 77.0 ppm for ¹³C NMR. All coupling constants *J* are quoted in Hz. FTIR spectra were obtained with a Bruker Tensor 27 instrument. All IR samples were prepared as thin film and reported in wave numbers (cm⁻¹). High resolution mass spectra (HRMS) were obtained on an IonSpec QFT mass spectrometer with ESI ionization.

Preparation of compound 13



To a solution of BH₃ THF (1 M, 0.60 mL, 0.6 mmol, 1.2 equiv) in THF at 0 $^{\circ}$ C was added cyclohexene (98.5 mg, 1.2 mmol, 2.4 equiv) in THF (1 mL). The mixture was stirred at 0 $^{\circ}$ C for 1 h. Then a solution of compound **12** (84 mg, 0.5 mmol, 1 equiv) in THF (1 mL) was added. The mixture was stirred at room temperature for another 1 h. The resulting solution was stirred at room temperature for 5 h after quenched by addition of NaBO₃ 4H₂O (280 mg, 1.8 mmol, 3.6 equiv) and water (2 mL) at 0 $^{\circ}$ C. The reaction mixture was extracted with EtOAc (5×3 mL). The combined solution

was concentrated and purified by column chromatography (2:1 petroleum ether:ethyl acetate) to give **S1** (75 mg, 0.4 mmol, 80%) as a clear oil. Data for **S1**: R_f 0.15 (2:1 petroleum ether:ethyl acetate); ¹H NMR (400 MHz, CDCl₃) δ 4.30 (t, J = 5.5 Hz, 2 H), 3.66-3.55 (m, 2 H), 1.90-1.82 (m, 2 H), 1.81-1.70 (m, 4 H), 1.64-1.54 (m, 4 H), 0.90 (t, J = 7.4 Hz, 3 H); ¹³C NMR (100 MHz, CDCl₃) δ 176.1, 70.1, 62.7, 45.9, 35.1, 32.2, 29.1, 27.6, 21.3, 8.6; IR (thin film) v_{max} 3411, 2945, 2878, 1719, 1460, 1399, 1255, 1161; HRMS (ESI) Calcd for C₁₀H₁₉O₃ [M+H]⁺ 187.1329, found: 187.1333.

To a solution of **S1** (18.6 mg, 0.1 mmol, 1 equiv) and PPh₃ (53 mg, 0.2 mmol, 2.0 equiv) in THF (2 mL) was added a solution of DPPA (82 mg, 0.3 mmol, 3.0 equiv) in THF (1 mL) and DIAD (61 mg, 0.3 mmol, 3.0 equiv) at 0 °C. The reaction mixture was stirred at 0 °C for 2 h. The reaction mixture was concentrated and purified by column chromatography (8:1 petroleum ether:ethyl acetate) to give compound **13** (19 mg, 0.09 mmol, 90%) as a clear oil. Data for compound **13**: R_f 0.45 (4:1 petroleum ether:ethyl acetate); ¹H NMR (400 MHz, CDCl₃) δ 4.31 (t, *J* = 5.4 Hz, 2 H), 3.34-3.22 (m, 2 H), 1.90-1.84 (m, 2 H), 1.83-1.68 (m, 4 H), 1.65-1.55 (m, 4 H), 0.91 (t, *J* = 7.5 Hz, 3 H); ¹³C NMR (100 MHz, CDCl₃) δ 175.4, 70.1, 51.6, 45.9, 36.0, 32.0, 29.3, 24.1, 21.2, 8.6; IR (thin film) v_{max} 2967, 2879, 2096, 1723, 1462, 1252; HRMS (ESI) Calcd for C₁₀H₁₈N₃O₂ [M+H]⁺ 212.1394, found: 212.1396.

Preparation of compound 14



To a solution of compound **13** (21 mg, 0.1 mmol, 1 equiv) in CH₂Cl₂ (2 mL) was added DIBAL-H (1.0 M in toluene, 0.15 mmol, 1.2 equiv) at -78 $^{\circ}$ C slowly. After stirred for 30 min at the same temperature, the mixture was quenched with MeOH (2 mL) carefully. Anhydrous K₂CO₃ (27.2 mg, 0.2 mmol, 2 equiv) and dimethyl-1-diazo-2-oxopropylphosphonate (28.8 mg, 1.5 mmol, 1.5 equiv) was added. The mixture was stirred at room temperture for 8 h. The reaction mixture was diluted with Et₂O (15 mL), washed with water (3×5 mL), dried over anhydrous Na₂SO₄, and filtered. Solvent was removed under reduced pressure to give a light yellow oil. The crude product was purified by column chromatography (8:1 petroleum ether:ethyl

acetate) to give compound **14** (15 mg, 0.072 mmol, 72%) as a clear oil. Data for compound **14**: $R_f 0.36$ (4:1 petroleum ether:ethyl acetate); ¹H NMR (400 MHz, CDCl₃) δ 3.66 (t, J = 6.4 Hz, 2 H), 3.29 (t, J = 6.7 Hz, 2 H), 2.12 (s, 1 H), 1.74-1.60 (m, 5 H), 1.54-1.44 (m, 6 H), 0.93 (t, J = 7.4 Hz, 3 H); ¹³C NMR (100 MHz, CDCl₃) δ 89.3, 70.3, 63.1, 51.8, 38.1, 34.7, 33.7, 30.6, 27.6, 24.0, 8.5; IR (thin film) v_{max} 3369, 3301, 2944, 2876, 2095, 1454, 1258, 1058; HRMS (ESI) Calcd for $C_{11}H_{20}N_3O_3$ [M+H]⁺ 210.1601, found: 210.1605.

Preparation of compound 15



To a solution of compound **14** (209 mg, 1.0 mmol, 1 equiv) in acetone (10 mL) was added a solution of CrO₃ in H₂SO₄ (8 N, about 2 mL) at 0 °C dropwise until the solution remained orange. The mixture was stirred for 10 min before water (20 mL) was added. The reaction mixture was extracted with Et₂O (5×5 mL), dried over anhydrous Na₂SO₄, and filtered. Solvent was removed under reduced pressure to give a brown oil. The crude product was diluted with MeOH (10 mL) at 0 °C and AcCl (0.2 mL) was added. After stirred for 2 h, the mixture was concentrated and purified by column chromatography (16:1 petroleum ether:ethyl acetate) to give **S3** (201 mg, 0.85 mmol, 85%) as a clear oil. Data for **S3**: R_f 0.46 (8:1 petroleum ether:ethyl acetate); ¹H NMR (400 MHz, CDCl₃) δ 3.68 (s, 3 H), 3.30 (t, *J* = 6.7 Hz, 2 H), 2.49-2.40 (m, 2 H), 2.16 (s, 1 H), 1.80-1.76 (m, 2 H), 1.74-1.66 (m, 2 H), 1.53-1.45 (m, 4 H), 0.94 (t, *J* = 7.5 Hz, 3 H); ¹³C NMR (100 MHz, CDCl₃) δ 174.0, 88.1, 71.1, 51.7, 51.6, 38.0, 34.6, 32.5, 30.5, 29.6, 24.0, 8.4; IR (thin film) v_{max} 3293, 2952, 2880, 2097, 1737, 1452, 1437, 1196, 1175; HRMS (ESI) Calcd for C₁₂H₂₀N₃O₂ [M+H]⁺ 238.1556, found: 238.1550.

To a stirred mixture of Pd(PPh₃)₂Cl₂ (90 mg, 0.13 mmol, 5 mol%), and CuI (34 mg, 0.18 mmol, 7 mol%) was added a solution of compound **S3** (610 mg, 2.57 mmol, 1 equiv) and **S4** (1.64 g, 5.15 mmol, 2.0 equiv) in a mixture of NEt₃ (6 mL) and THF (6 mL) at -78 $^{\circ}$ C under Argon. The reaction mixture was then degassed by freeze-thaw

cycles before it was stirred at room temperature for 12 h. The reaction mixture was filtered through a pad of Celite. Solvents were removed under reduced pressure and the crude product was purified by column chromatography (16:1 petroleum ether:ethyl acetate) to give compound **15** (892 mg, 2.08 mmol, 81%) as a yellow oil. Data for compound **15**: $R_f 0.47$ (8:1 petroleum ether:ethyl acetate); ¹H NMR (400 MHz, CDCl₃) δ 8.07 (d, J = 8.3 Hz, 1 H), 7.33-7.19 (m, 3 H), 6.93 (td, J = 7.6 Hz, 1.1, 1 H), 3.67 (s, 3 H), 3.34 (t, J = 6.5 Hz, 2 H), 2.49 (t, J = 8.0 Hz, 2 H), 1.90 (t, J = 6.4 Hz, 2 H), 1.80-1.70 (m, 2 H), 1.69-1.58 (m, 4 H), 1.51 (s, 9 H), 1.04 (t, J = 7.4 Hz, 3 H); ¹³C NMR (100 MHz, CDCl₃) δ 173.8, 152.3, 139.4, 131.4, 129.1, 122.0, 117.4, 111.4, 100.7, 80.6, 79.1, 51.7, 51.6, 39.1, 34.9, 32.7, 30.9, 29.8, 28.2, 24.2, 8.8; IR (thin film) v_{max} 3402, 2970, 2937, 2878, 2097, 1735, 1580, 1517, 1449, 1367, 1238, 1157, 755, 591; HRMS (ESI) Calcd for C₂₁H₃₂N₄O₄Na [M+Na]⁺ 451.2316, found: 451.2316.

Preparation of compound 16



To a solution of compound 15 (730 mg, 1.36 mmol, 1 equiv) in CCl₄ (6 mL) and MeCN (6 mL) was added NaIO₄ (732 mg, 3.40 mmol, 2.5 equiv) in H₂O (9 mL). The reaction mixture was stirred vigorously while RuO₂•H₂O (9.0 mg, 0.067 mmol, 5 mol%) was added. The reaction mixture was stirred vigorously in air for 2 h before filtered through a pad of silica gel with CH₂Cl₂ as the eluent. The filtrate was washed with an aqueous solution of NaOH (1.0 N, 2×5 mL) and dried over anhydrous Na₂SO₄, and filtered. Solvent was removed under reduced pressure to give a dark color oil. The crude product was purified by column chromatography (8:1 petroleum ether:ethyl acetate) to give compound 16 as a yellow oil (509 mg, 0.89 mmol, 66%). Data for compound **16**: $R_f 0.40$ (8:1 petroleum ether:ethyl acetate); ¹H NMR (400 MHz, CDCl₃) δ 10.52 (s, 1 H), 8.55 (d, J = 8.8 Hz, 1 H), 7.57 (t, J = 8.0 Hz, 1 H), 7.40 (d, J = 7.6 Hz, 1 H), 7.01 (t, J = 7.6 Hz, 1 H), 3.67 (s, 3 H), 3.28 (t, J = 6.5 Hz, 2 H), 2.35-2.25 (m, 2 H), 2.10-1.99 (m, 2 H), 1.78-1.68 (m, 4 H), 1.62-1.50 (m, 11 H), 0.88 (t, J = 7.4 Hz, 3 H); ¹³C NMR (100 MHz, CDCl₃) δ 206.7, 197.9, 173.4, 152.6, 143.5, 136.6, 133.1, 121.0, 119.3, 116.7, 81.2, 52.3, 51.8, 51.6, 30.5, 28.7, 28.2, 26.8, 26.3, 23.4, 8.0; IR (thin film) v_{max} 3402, 2970, 2937, 2878, 2097, 1735, 1580, 1517, 1449, 1367, 1238, 1157, 755, 591; HRMS (ESI) Calcd for $C_{23}H_{33}N_4O_6$ [M+H]⁺ 461.2395, found: 461.2393.

Preparation of compound 17



To a solution of compound 16 (35 mg, 0.076 mmol, 1 equiv) and 2,6-lutidine (163 mg, 1.52 mmol, 20 equiv) in CH₂Cl₂ (4 mL) was added TMSOTf (169 mg, 0.76 mmol, 10 equiv) was added dropwise at 0 °C. The reaction mixture was stirred for 1 h and then diluted with CH₂Cl₂ (10 mL) at 0 °C, washed with a cold aqueous solution of HCl (1%, 4×5 mL) quickly and dried over anhydrous MgSO₄, and filtered. Solvent was removed under reduced pressure to give a brown oil. The crude product was purified by column chromatography (4:1 petroleum ether:ethyl acetate) to give compound 17 as a yellow oil (19 mg, 0.05 mmol, 69%). Data for compound 17: Rf 0.26 (4:1 petroleum ether:ethyl acetate); ¹H NMR (400 MHz, CDCl₃) δ 7.34-7.26 (m, 2 H), 6.68 (d, J = 8.0 Hz, 1 H), 6.62 (t, J = 7.6 Hz, 1 H), 6.32 (bs, 2 H), 3.67 (s, 3 H), 3.27 (t, J = 6.7 Hz, 2 H), 2.35-2.28 (m, 2 H), 2.10-2.01 (m, 2 H), 1.78-1.69 (m, 4 H), 1.60-1.52 (m, 2 H), 0.89 (t, J = 7.4 Hz, 3 H); ¹³C NMR (100 MHz, CDCl₃) δ 207.6, 196.4, 173.6, 151.8, 135.8, 132.7, 125.2, 117.4, 116.2, 52.2, 51.7, 30.7, 29.6, 28.9, 28.8, 26.3, 23.5, 8.1; IR (thin film) v_{max} 3448, 2951, 2879, 1734, 1671, 1581, 1564, 1471, 1296, 1169, 774, 703; HRMS (ESI) Calcd for C₁₈H₂₅N₄O₄ [M+H]⁺ 361.1870, found: 361.1868.^[1]

Synthesis of mersicarpine (1)



To a solution of compound **17** (10 mg, 0.027 mmol, 1 equiv) in THF (2 mL) and H_2O (0.2 mL) was added PPh₃ (30 mg, 0.111 mmol, 4 equiv). The reaction mixture was stirred at room temperature for 3 days before THF (10 mL) and anhydrous MgSO₄ were added. The mixture was filtered and concentrated under reduced pressure. The

crude product was purified by column chromatography (4:1 petroleum ether:ethyl acetate) to give mersicarpine (**1**) (5 mg, 0.018 mmol, 66%) as a light yellow oil. Data for synthetic mersicarpine (**1**): R_f 0.38 (2:1 petroleum ether:ethyl acetate); ¹H NMR (400 MHz, CDCl₃) δ 8.14 (d, J = 8.4 Hz, 1 H), 7.60 (d, J = 7.6 Hz, 1 H), 7.37 (t, J = 7.8 Hz, 1 H), 7.07 (t, J = 7.4 Hz, 1 H), 3.90-3.84 (m, 2 H), 2.60 (ddd, J = 18.3, 9.5, 3.2 Hz, 1 H), 2.47-2.36 (m, 1 H), 2.05 (d, J = 15.0 Hz, 1 H), 1.97-1.87 (m, 1 H), 1.80-1.72 (m, 1 H), 1.72-1.63 (m, 3 H), 1.39-1.29 (m, 1 H), 1.17-1.08 (m, 1 H), 0.75 (t, J = 7.4 Hz, 3 H); ¹³C NMR (100 MHz, CDCl₃) δ 169.4, 168.4, 146.5, 133.2, 124.4, 124.3, 122.1, 116.8, 93.8, 50.7, 39.3, 34.3, 29.2, 25.4, 23.0, 21.2, 6.8; IR (thin film) v_{max} 3283, 2955, 2856, 1586, 1485, 1456, 1255, 1081, 969, 838, 757, 674; HRMS (ESI) Calcd for C₁₇H₂₁N₂O₂ [M+H]⁺ 285.1603, found: 285.1602.

Preparation of compound 18



To a solution of compound **17** (10 mg, 0.027 mmol, 1 equiv) in anhydrous THF (2 mL) was added PPh₃ (30 mg, 0.111 mmol, 4 equiv). The solution was stirred at room temperature for 3 days. The mixture was concentrated under reduced pressure and purified by column chromatography (4:1 petroleum ether:ethyl acetate) to give compound **18**, a pair of inseparable diastereomers (1:1, 6 mg, 0.019 mmol, 68%) as a light yellow oil. Data for compound **18**: R_f 0.28 (2:1 petroleum ether:ethyl acetate); ¹H NMR (400 MHz, CDCl₃) δ 7.56-7.44 (m, 1 H), 7.42-7.34 (m, 1 H), 6.77-6.70 (m, 2 H), 4.64-4.40 (m, 1 H), 3.62 (s, 1.5 H), 3.52 (s, 1.5 H), 3.42-3.25 (m, 1 H), 2.81-2.70 (m, 1 H), 2.34-2.10 (m, 4 H), 2.04-1.93 (m, 1 H), 1.73-1.35 (m, 4 H), 1.33-1.23 (m, 1 H), 0.80 (t, *J* = 7.3 Hz, 1.5 H), 0.72 (t, *J* = 7.5 Hz, 1.5 H); ¹³C NMR (100 MHz, CDCl₃) δ 201.5, 201.0, 174.7, 174.4, 159.4, 159.1, 137.1, 125.1, 124.9, 120.2, 120.0, 119.2, 118.9, 112.0, 111.9, 79.97, 79.92, 51.6, 51.4, 39.9, 39.8, 39.7, 39.5, 29.2, 29.1, 28.7, 28.2, 27.7, 27.1, 25.7, 22.4, 21.0, 20.9, 8.5, 7.5; IR (thin film) v_{max} 3370, 2947, 2878, 1731, 1692, 1617, 1485, 1468, 1437, 1319, 1195, 1076, 753; HRMS (ESI) Calcd for C₁₈H₂₅N₂O₃ [M+H]⁺ 317.1860, found: 317.1858.

Preparation of compound 11



To a solution of compound 18 (100 mg, 0.32 mmol, 1 equiv) in toluene (5 mL) was added NaH (washed with hexane, 12 mg, 0.50 mmol, 1.5 equiv) in one portion. The suspension was stirred at 50 °C for 12 h before the reaction was quenched with a saturated aqueous solution of NH₄Cl. The mixture was extracted with EtOAc (3×5 mL). The combined solution was dried over anhydrous MgSO₄, and filtered. Solvent was removed under reduced pressure. The crude product was purified by column chromatography (4:1 petroleum ether:ethyl acetate) to give compound 11 (77 mg, 0.27 mmol, 85%) as a light yellow oil. Data for compound 11: $R_f 0.45$ (2:1 petroleum ether:ethyl acetate); ¹H NMR (400 MHz, CDCl₃) δ 8.41 (d, J = 8.4 Hz, 1 H), 7.67 (d, J = 7.6 Hz, 1 H), 7.61-7.54 (m, 1 H), 7.17 (t, J = 7.4 Hz, 1 H), 3.22 (dt, J = 12.4, 3.3 Hz, 1 H), 2.91-2.77 (m, 2 H), 2.63-2.43 (m, 2 H), 2.34-2.21 (m, 1 H), 1.86-1.76 (m, 1 H), 1.73-1.51 (m, 4 H), 1.35 (m, 1 H), 1.28-1.18 (m, 1 H), 0.78 (t, J = 7.5 Hz, 3 H); ¹³C NMR (100 MHz, CDCl₃) δ 195.9, 169.6, 151.1, 136.7, 124.3, 124.2, 121.7, 118.2, 80.4, 39.8, 36.6, 29.8, 29.0, 26.4, 23.3, 20.2, 6.8; IR (thin film) v_{max} 3380, 2965, 2856, 1730, 1693, 1566, 1456, 1255, 1081, 750, 574; HRMS (ESI) Calcd for C₁₇H₂₁N₂O₂ [M+H]⁺285.1603, found: 285.1602.

Preparation of compound 19



To compound **11** (80 mg, 0.28 mmol, 1 equiv) was added Ac₂O (5 mL). The solution was stirred at room temperature for 12 h before concentrated under reduced pressure. The residue was purified by column chromatography (2:1 petroleum ether:ethyl acetate) to give compound **19** (83 mg, 0.25 mmol, 90%) as a white powder. Data for compound **19**: R_f 0.25 (1:1 petroleum ether:ethyl acetate); ¹H NMR (400 MHz, CDCl₃) δ 8.42 (d, J = 8.4 Hz, 1 H), 7.67 (d, J = 7.6 Hz, 1 H), 7.62 (t, J = 7.8 Hz, 1 H), 7.18 (t, J = 7.4 Hz, 1 H), 3.86-3.76 (m, 1 H), 3.68-3.60 (m, 1 H), 2.86-2.72 (m, 1 H),

2.54-2.48 (m, 1 H), 2.19-2.08 (m, 1 H), 2.04 (s, 3 H), 2.02-1.90 (m, 4 H), 1.79-1.69 (m, 1 H), 1.18-1.09 (m, 2 H), 0.73 (t, J = 7.5 Hz, 3 H); ¹³C NMR (100 MHz, CDCl₃) δ 196.7, 171.3, 168.9, 152.0, 136.7, 124.0, 123.7, 122.7, 117.0, 81.1, 43.8, 40.6, 30.8, 28.9, 28.1, 26.5, 23.9, 20.2, 7.0; IR (thin film) v_{max} 2966, 2943, 1729, 1693, 1679, 1452, 1368, 1295, 1008, 767, 756, 574; HRMS (ESI) Calcd for C₁₉H₂₃N₂O₃ [M+H]⁺ 327.1709, found: 327.1709; mp = 200-202 °C.^[2]

Synthesis of leuconodine B (3)



To a solution of compound **19** (10 mg, 0.031 mmol, 1 equiv) in THF (3 mL) was added LDA (2.0 M in THF, 30.0 µL, 0.06 mmol, 2 equiv) at -78 °C. The reaction mixture was stirred for 2 h before it was quenched by dropwise addition of a saturated aqueous solution of NH₄Cl. The mixture was warmed to room temperature, diluted with water (5 mL), extracted with EtOAc (3×5 mL). The combined solution was dried over anhydrous MgSO₄, and filtered. Solvent was removed under reduced pressure. The crude product was purified by column chromatography (4:1 petroleum ether:ethyl acetate) to give leuconodine B (3) (7.2 mg, 0.022 mmol, 72%) as a white powder. Data for leuconodine B (3): $R_f 0.40$ (2:1 petroleum ether:ethyl acetate); ¹H NMR (400 MHz, CDCl₃) δ 7.60 (d, J = 7.6 Hz, 1 H), 7.39 (d, J = 7.2 Hz, 1 H), 7.27 (t, J = 8.0 Hz, 1 H), 7.20 (t, J = 7.4 Hz, 1 H), 4.81 (s, 1 H), 3.89 (d, J = 13.2 Hz, 1 H), 2.97 (d, J = 16.8 Hz, 1 H), 2.87 (d, J = 16.4 Hz, 1 H), 2.52 (t, J = 12.2 Hz, 1 H), 2.29-2.13 (m, 2 H), 1.95-1.87 (m, 1 H), 1.82-1.71 (m, 2 H), 1.61-1.51 (m, 4 H), 1.47-1.41 (m, 1 H), 0.87 (t, J = 7.4, 3 H); ¹³C NMR (100 MHz, CDCl₃) δ 174.2, 169.9, 140.9, 138.3, 129.2, 126.2, 123.3, 121.9, 90.9, 82.1, 42.1, 39.1, 37.0, 28.1, 27.5, 25.9, 22.5, 20.0, 6.9; IR (thin film) v_{max} 3448, 2949, 2943, 1693, 1646, 1477, 1405, 1363, 1270, 1153, 766, 734; HRMS (ESI) Calcd for $C_{19}H_{23}N_2O_3$ [M+H]⁺ 327.1709, found: 327.1707; mp = 317-319 °C.

Preparation of compound 20



To leuconodine B (**3**) (2 mg, 6.1 µmol, 1 equiv) was added SOCl₂ (1.5 mL) at room temperature. The reaction mixture was stirred for 1 h before SOCl₂ was removed under reduced pressure. The residue was purified by column chromatography (4:1 petroleum ether:ethyl acetate) to give compound **20** (2 mg, 5.8 µmol , 95%) as a clear oil. Data for compound **20**: R_f 0.41 (2:1 petroleum ether:ethyl acetate); ¹H NMR (400 MHz, CDCl₃) δ 7.78 (d, *J* = 8.0 Hz, 1 H), 7.34 (m, 2 H), 7.21 (t, *J* = 7.6 Hz, 1 H), 3.98 (m, 1 H), 3.27 (d, *J* = 16.4 Hz, 1 H), 3.20 (d, *J* = 16.4 Hz, 1 H), 2.89-2.75 (m, 1 H), 2.74-2.50 (m, 3 H), 2.27-2.14 (m, 1 H), 2.07-1.97 (m, 1 H), 1.88-1.77 (m, 1 H), 1.76-1.60 (m, 3 H), 1.57-1.47 (m, 1 H), 0.93 (t, *J* = 7.0 Hz, 3 H); ¹³C NMR (100 MHz, CDCl₃) δ 172.4, 167.9, 140.0, 136.3, 129.9, 126.2, 122.8, 120.7, 91.8, 69.2, 44.9, 39.9, 37.2, 29.3, 27.8, 25.0, 22.0, 19.8, 6.9; IR (thin film) v_{max} 2951, 2882, 1704, 1686, 1600, 1477, 1463, 1397, 1352, 1284, 1151, 903, 801, 734; HRMS (ESI) Calcd for C₁₉H₂₂ClN₂O₂ [M+H]⁺ 345.1364, found: 345.1360.

Synthesis of leuconolam (5)



To a solution of compound **20** (12 mg, 0.035 mmol, 1 equiv) in THF (1.5 mL) was added DBU (27 mg, 0.175 mmol, 5.0 equiv). The reaction mixture was stirred at room temperature for 8 h. H₂SO₄ (3N, 2 mL) was added to the mixture, then the mixture was heated to 50 °C. After stirring for 1 h, the solution was extracted with EtOAc (3×2 mL). The combined solution was dried over anhydrous MgSO₄, and filtered. Solvent was removed under reduced pressure. The crude product was purified by column chromatography (1:1 petroleum ether:ethyl acetate) to give leuconolam (**5**) (8.5 mg, 0.026 mmol, 75%) as a white solid. Data for leuconolam (**5**): R_f 0.22 (9:1 CHCl₃:MeOH); ¹H NMR (400 MHz, CDCl₃:CD₃OD = 3:1(v:v)) δ 7.81 (d, *J* = 8.0 Hz, 1 H), 7.40 (t, *J* = 7.6 Hz, 1 H), 7.32 (t, *J* = 7.6 Hz, 1 H), 7.22 (d, *J* = 7.6 Hz, 1 H), 5.92 (s, 1 H), 4.01-3.97 (m, 1 H), 2.95 (dt, *J* = 12.8, 4.8 Hz, 1 H), 2.16 (dd, *J* = 14.7, 7.4

Hz, 1 H), 1.98 (t, J = 12.9 Hz, 1 H), 1.83-1.72 (m, 1 H), 1.66-1.40 (m, 6 H), 1.30-1.20 (m, 1 H), 0.55 (t, J = 7.5 Hz, 3 H); ¹³C NMR (100 MHz, CDCl₃:CD₃OD = 3:1(v:v)) δ 178.6, 166.8, 156.3, 135.0, 133.0, 129.6, 128.9, 127.7, 126.6, 126.1, 93.5, 45.0, 35.1, 32.0, 27.5, 25.3, 24.1, 19.7, 6.7; IR (thin film) v_{max} 3737, 3067, 2963, 2945, 2870, 1677, 1648, 1458, 1438, 1385, 1261, 1086, 1027, 805; HRMS (ESI) Calcd for C₁₉H₂₃N₂O₂ [M+H]⁺ 327.1703, found: 327.1701; mp = 198-200 °C.

Synthesis of melodinine E (4)



To a solution of compound 20 (12 mg, 0.035 mmol, 1 equiv)in THF (1.5 mL) was added DBU (27 mg, 0.175 mmol, 5.0 equiv). The reaction mixture was stirred at room temperature for 8 h. Water (2 mL) was added to the mixture, and the mixture was extracted with EtOAc (3×2 mL). The combined solution was dried over anhydrous MgSO₄, and filtered. Solvent was removed under reduced pressure. The crude product was purified by column chromatography (4:1 petroleum ether:ethyl acetate) to give melodinine E (4) (9.7 mg, 0.031 mmol, 90%) as a clear oil. Data for melodinine E (4): $R_f 0.40$ (2:1 petroleum ether:ethyl acetate); ¹H NMR (400 MHz, CDCl₃) δ 8.16 (d, J = 8.4 Hz, 1 H), 7.45 (d, J = 7.2 Hz, 1 H), 7.33 (t, J = 7.4 Hz, 1 H), 7.12 (t, J = 7.4 Hz, 1 H), 6.21 (s, 1 H), 4.47 (ddd, J = 15.2, 11.7, 3.7, 1 H), 3.26-3.16 (m, 1 H), 3.09 (dt, J = 15.7, 6.2 Hz, 1 H), 2.64-2.58 (m, 1 H), 2.13-2.00 (m, 2 H), 1.83-1.63 (m, 3 H), 1.49-1.41 (m, 1 H), 1.40-1.30 (m, 1 H), 1.10 (dt, J = 13.5, 6.8 Hz, 1 H), 0.76 (t, J = 7.3 Hz, 3 H); 13 C NMR (100 MHz, CDCl₃) δ 176.1, 173.5, 164.3, 148.7, 131.6, 124.3, 123.5, 121.6, 118.2, 116.0, 93.6, 44.6, 37.0, 34.2, 33.1, 30.5, 26.1, 16.8, 8.3; IR (thin film) v_{max} 2963, 2880, 1689, 1648, 1597, 1456, 1371, 1356, 1261, 1095, 1021, 801; HRMS (ESI) Calcd for $C_{19}H_{21}N_2O_2 [M+H]^+ 309.1603$, found: 309.1601.

Synthesis of leuconoxine (2)



To a solution of melodinine E (4) (2.0 mg, µmol) in EtOAc (5 mL) was added Pd/C

(0.2 mg, 10% w/w). The reaction mixture was purged with H₂ and stirred under a pressure of H₂ (4 atm) at room temperature for 8 h. The reaction mixture was filtered through a pad of Celite, and washed with EtOAc (3×5 mL). The filtrate was concentrated under reduced pressure and purified by column chromatography (4:1 petroleum ether:ethyl acetate) to give leuconoxine (2) (2.0 mg, 6.5 µmol, 99%) as a white powder. Data for leuconoxine (2): R_f 0.30 (1:1 petroleum ether:ethyl acetate); ¹H NMR (400 MHz, CDCl₃) δ 7.77 (d, *J* = 8.0 Hz, 1 H), 7.26-7.22 (m, 1 H), 7.19-7.12 (m, 2 H), 3.95 (d, *J* = 13.2 Hz, 1 H), 3.82 (d, *J* = 7.2 Hz, 1 H), 2.92-2.66 (m, 4 H), 2.54-2.45 (m, 1 H), 2.02-1.92 (m, 1 H), 1.90-1.76 (m, 2 H), 1.70-1.54 (m, 4 H), 1.43-1.32 (m, 1 H), 0.92 (t, *J* = 7.2 Hz, 3 H); ¹³C NMR (100 MHz, CDCl₃) δ 172.9, 170.8, 142.0, 135.1, 128.0, 125.5, 123.9, 120.1, 92.6, 41.9, 38.1, 37.6, 36.8, 29.4, 26.9, 26.6, 26.2, 20.1, 7.3; IR (thin film) *v*_{max} 2947, 2867, 1677, 1476, 1457, 1397, 1361, 1143, 1086, 888, 761; HRMS (ESI) Calcd for C₁₉H₂₃N₂O₂ [M+H]⁺ 311.1760, found: 311.1754; mp = 188-190 °C.

Preparation of (-)-12



To a solution of **24** (143 mg, 0.498 mmol) in ethanol (10 mL) was added NaBH₄ (188 mg, 4.98 mmol) portionwise at 0 $^{\circ}$ C. After the starting material was shown to be consumed by TLC analysis, 2 M aqueous NaOH (0.30 mL) was added to the reaction mixtureat 0 $^{\circ}$ C. The resulting mixture was slowly warmed up to room temperature and stirred overnight. 1M aqueous HCl, saturated Rochelle's salt aqueous solution and CH₂Cl₂ were added to the reaction mixture. The mixture was stirred for 2 h and the phases were separated. The aqueous phase was extracted with CH₂Cl₂ twice. The combined organic phases were dried over Na₂SO₄, filtered and concentrated under reduced pressure. The crude product was used for the next reaction without further purification.

To a solution of **25** in toluene (5.0 mL) was added *p*-toluenesulfonic acid monohydrate (114 mg, 0.598 mmol) and the reaction mixture was heated at 60 °C for 3 h. The reaction mixture was cooled to room temperature and purified by flash column chromatography (6:1 petroleum ether:ethyl acetate) to afford (–)-**12** (45.0 mg, 0.267 mmol, 54% in 2 steps) as a colorless oil. Data for (–)-**12**: $R_f = 0.35$ (6:1 petroleum ether:ethyl acetate); ¹H NMR (500 MHz, CDCl₃) δ 5.75 (m, 1 H), 5.14–5.07 (m, 2 H), 4.29 (m, 2 H), 2.53 (m, 1 H), 2.19 (m, 1 H), 1.88–1.72 (m, 5 H), 1.55 (m, 1 H), 0.92 (t, *J* = 7.5 Hz, 3 H); ¹³C NMR (126 MHz, CDCl₃) δ 175.4, 133.8, 118.9, 70.2, 46.5, 43.8, 32.4, 28.9, 21.4, 8.9; IR (Neat Film,NaCl) 2966, 1724, 1453, 1397, 1249, 1142, 1075, 917; HRMS (ESI+) *m*/*z* calc'd for C₁₀H₁₇O₂ [M+H]⁺: 169.1223, found 169.1218; [α]_D²⁵ = -8.0 (*c* = 0.97, CHCl₃).

Table 1: Chemical shifts of ¹³C NMR data for natural, synthetic mersicarpine (1) reported previously and our synthetic mersicarpine (1).



mersicarpine (1)

Natural mersicarpine	Synthetic mersicarpine	Synthetic mersicarpine
(Prof. Kam, TS.) ^[3]	(Prof. Kerr, M. A.) ^[4]	(Prof. Liang, G. X.)
(100 MHz, CDCl ₃)	(100 MHz, CDCl ₃)	(100 MHz, CDCl ₃)
169.6	169.5	169.4
168.9	168.8	168.4
146.5	146.5	146.5
133.2	133.2	133.2
124.4	124.3	124.4
124.2	124.3	124.1
122.2	122.2	122.1
116.7	116.7	116.8
93.8	93.8	93.8
50.5	50.5	50.7
39.3	39.3	39.3
34.3	34.3	34.3
29.1	29.1	29.2
25.4	25.4	25.4
22.9	22.9	23.0
21.1	21.1	21.2
6.8	6.8	6.8

Table 2: Chemical shifts of ¹³C NMR data for natural, synthetic leuconodine B (3) reported previously and our synthetic leuconodine B (3).



leuconodine B (3)

Natural	Natural	Synthetic	Synthetic
leuconodine B	scholarisine G	leuconodine B	leuconodine B
(Prof. Kam, TS.) ^[5]	(Prof. Luo, XD.) ^[6]	(Prof. Zhu, JP.) ^[2]	(Prof. Liang, G. X.)
(100 MHz, CDCl ₃)	(100 MHz, CDCl ₃)	(100 MHz, CDCl ₃)	(100 MHz, CDCl ₃)
173.6	173.2	173.6	174.2
170.0	169.9	170.0	169.9
141.3	141.3	141.5	140.9
137.4	136.9	137.3	138.3
129.4	129.9	129.9	129.2
125.6	125.8	125.9	126.2
122.9	122.7	123.0	123.3
120.7	120.8	120.9	121.9
90.4	90.5	90.7	90.9
81.9	82.0	82.1	82.1
42.2	42.1	42.3	42.1
39.1	39.1	39.3	39.1
36.8	36.8	37.0	37.0
29.5	29.5	29.6	28.1
27.2	27.2	27.4	27.5
25.5	25.6	25.7	25.9
22.4	22.5	22.7	22.5
20.0	20.0	20.2	20.0
6.9	6.9	7.1	6.9

 Table 3: Chemical shifts of ¹³C NMR data for natural, synthetic leuconolam (5)

 reported previously and our synthetic leuconolam (5).



leuconolam (5)

Natural	Synthetic	Synthetic
(–)-leuconolam	(±)-leuconolam	(±)-leuconolam
(Prof. Goh.S.H.) ^[7]	(Prof. Zhu, JP.) ^[2]	(Prof. Liang, G. X.)
(100 MHz, CDCl ₃)	(100 MHz,	(100 MHz,
	$CDCl_3/CD_3OD = 3/1)$	$CDCl_3/CD_3OD = 3/1)$
177.8	179.3	178.6
166.5	167.5	166.7
155.6	157.0	156.3
135.0	135.7	135.0
133.1	133.7	133.0
129.4	130.3	129.6
129.3	129.6	128.9
128.1	128.4	127.7
126.6	127.3	126.6
126.3	126.9	126.1
93.6	94.2	93.5
44.9	45.7	45.0
35.3	35.8	35.1
32.1	32.7	32.0
27.3	28.3	27.5
25.4	26.0	25.3
24.5	24.8	24.0
19.7	20.4	19.7
6.9	7.5	6.7

Table 4: Chemical shifts of 13 C NMR data for natural, synthetic melodinine E (4) reported previously and our synthetic melodinine E (4).



melodinine E (4)

Natural	Synthetic	Synthetic
melodinine E	melodinine E	melodinine E
(Prof. Luo, XD.) ^[8]	(Prof. Zhu, JP.) ^[2]	(Prof. Liang, G. X.)
(100 MHz, CDCl ₃)	(100 MHz, CDCl ₃)	(100 MHz, CDCl ₃)
176.0	176.2	176.1
173.5	173.6	173.5
164.2	164.4	164.3
148.5	148.8	148.7
131.5	131.7	131.6
124.3	124.5	124.3
123.4	123.6	123.5
121.5	121.7	121.6
118.1	118.3	118.2
115.8	116.0	116.0
93.5	93.8	93.6
44.5	44.7	44.6
36.9	37.1	37.0
34.1	34.3	34.2
33.1	33.2	33.1
30.4	30.5	30.5
26.0	26.2	26.1
16.7	16.9	16.8
8.2	8.4	8.3

 Table 5: Chemical shifts of ¹³C NMR data for natural, synthetic leuconoxine (2)

 reported previously and our synthetic leuconoxine (2).



leuconoxine (2)

Natural	Synthetic	Synthetic	Synthetic
leuconoxine	leuconoxine	leuconoxine	leuconoxine
(Prof. Abe, F.) ^[9]	(Prof. Baudoin, O.) ^[10]	(Prof. Zhu, JP.) ^[2]	(Prof. Liang, G. X.)
(100 MHz, CDCl ₃)	(100 MHz, CDCl ₃)	(100 MHz, CDCl ₃)	(100 MHz, CDCl ₃)
172.8	173.0	173.1	172.9
170.7	171.0	171.0	170.8
142.0	141.6	142.1	142.0
135.1	135.3	135.2	135.1
127.9	128.2	128.1	128.0
125.5	125.7	125.7	125.5
123.8	124.0	124.0	123.9
120.1	120.3	120.2	120.1
92.5	92.2	92.7	92.6
41.9	42.1	42.1	41.9
38.1	38.3	38.2	38.1
37.5	37.8	37.7	37.6
36.8	37.0	36.9	36.8
29.4	29.6	29.5	29.4
27.0	27.1	27.0	26.9
26.7	26.9	26.7	26.6
27.3	26.4	26.4	26.2
20.1	20.3	20.2	20.1
7.3	7.5	7.4	7.3

Reference and Note:

- [1] Compound **17** is unstable while being kept at room temperature for a long time. It is also sensitive to acid, base and heat. Therefore, it could not be isolated with high purity.
- [2] Xu, Z.; Wang, Q.; Zhu, J. J. Am. Chem. Soc. 2013, 135, 19127–19130.
- [3] Kam, T.-S.; Subramaniam, G.; Lim, K.-H.; Choo, Y.-M. *Tetrahedron Lett.* **2004**, *45*, 5995–5998.
- [4] Magolan, J.; Carson, C. A.; Kerr, M. A. Org. Lett. 2008, 10, 1437–1440.
- [5] Gan, C.-Y.; Low, Y.-Y.; Thomas, N. F.; Kam, T.-S. J. Nat. Prod. 2013, 76, 957–964.
- [6] Feng, T.; Cai, X.-H.; Zhao, P.-J.; Du, Z.-Z.; Li, W.-Q.; Luo, X.-D. Planta Med. 2009, 75, 1537–1541.
- [7] S.H. GOH.; Razak Mohd Ali, A.; Wong , W.H.. Tetrahedron, 1989, 45, 7899–7920
- [8] Feng, T.; Cai, X.-H.; Liu, Y.-P.; Li, Y.; Wang, Y.-Y.; Luo, X.-D. J. Nat. Prod. 2010, 73, 22–26.
- [9] Abe, F.; Yamaguchi, T. *Phytochemistry* **1994**, *35*, 169–171.
- [10] De'cor, A.; Bellocq, D.; Thoison, O.; Lekieffre, N.; Chiaroni, A.; Ouazzani, J.; Cresteil, T.; Gue'ritte, F.; Baudoin, O. *Bioorg. Med. Chem.* 2006, 14, 1558–1564.



¹H NMR and ¹³C NMR Spectra




































































HRMS (ESI) Calcd for $C_{19}H_{22}CIN_2O_2 [M+H]^+ 345.1364$ (21)